Please assess the completion status of the following clinical trial:

Trial Title: Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Male or female patients, aged 10 years and above, with β-thalassemia major or DBA or sideroblastic anemia on chronic transfusion therapy, having given written consent to participate in the study.~* Patients with cardiac iron as measured by a myocardial T2\* value that is ≥ 6ms but not ≥ 20 ms.~* Patients with a lifetime history of at least 50 units of red cell transfusions, and must be receiving at least ≥10 units/yr of red blood cells transfusions.~* Patients with a left ventricular ejection fraction (LVEF) ≥ 56 % as determined by cardiovascular magnetic resonance (CMR).~* Patients with liver iron content (LIC) value ≥ 3 mg Fe / g dw, as determined by liver MRI.~Exclusion criteria:~* Patients with clinical symptoms of cardiac dysfunction.~* Patients unable to undergo study assessments including MRI~* Patients participating in another clinical trial or receiving an investigational drug.~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Deferasirox (Type: EXPERIMENTAL): 20 mg/kg/day once daily (od) for 2 weeks, followed by 30 mg/kg/day od for 1 week and a subsequent continuation of 40 mg/kg/day
- Deferasirox Placebo (Type: ACTIVE_COMPARATOR): 50 mg/kg/day to 60 mg/kg/day infused subcutaneously in 8- to 12-hour intervals administered 5 to 7 days/week
- Extension: deferoxamine to deferasirox (Type: EXPERIMENTAL): DFO to ICL (patients who switched from DFO to deferasirox in extension)
- Extension: deferasirox to deferoxamine (Type: EXPERIMENTAL): ICL to DFO (patients who switched from deferasirox to DFO in extension)

Based on this trial design, predict the completion outcome and termination type (if applicable).